News
-
VentureWise splits with MedReleaf
Monday | Feb 12 2018NPS MedicineWise offshoot VentureWise has formally announced the discontinuation of its partnership with medicinal cannabis company MedReleaf (PD 06 Feb), which included the development of educational resources on medicinal cannabis for pharmacists, GPs and specialists.
-
Events Calendar 9 Feb 18
Friday | Feb 9 201816-18 Mar: Annual Therapeutic Update 2018; Fairmont Resort, Blue Mountains; for details and registrations visit: www.psa.org.au,.
-
Dispensary Corner 09 Feb 18
Friday | Feb 9 2018TYPICALLY, providing medical advice to pregnant women doesn't extend to the colour of the snacks they are eating, however one mum from England thinks maybe it should.
-
Pain alternative?
Friday | Feb 9 2018THE compounding pharmacy sector may have a "gentler, non-addictive answer" for sufferers of chronic pain, according to National Custom Compounding (NCC), which is highlighting the benefits of palmitoyletanolaminde (PEA).
-
SafeScript regulations
Friday | Feb 9 2018THE Victorian Government has released the details of proposed new legislation governing the operation of the state's SafeScript real-time prescription monitoring system (PD 20 Oct 2017), with input from stakeholders sought.
-
Indications under fire
Friday | Feb 9 2018A proposed new TGA list of permitted indications for complementary medicines has been blasted as "bizarre" and "not supported by scientific evidence" in a major Fairfax report today.
-
Malaria drug review
Friday | Feb 9 2018THE US Food and Drug Administration has granted Priority Review Designation for a new drug to help prevent malaria.
-
New data breach laws
Friday | Feb 9 2018MOST community pharmacies in Australia will be subject to new legislation on "data breaches" when the laws come into effect on 22 Feb 2018, after being passed by Federal Parliament this week.
-
Cost consultation
Friday | Feb 9 2018THE Therapeutic Goods Administration has opened a public consultation on its current good manufacturing practice (GMP) fees and charges.
-
Bipolar 1 approval
Friday | Feb 9 2018LUNDBECK and Otsuka have welcomed the approval of Abilify Maintena (aripiprazole once-monthly long-acting injectable) for the treatment of bipolar 1 disorder.
